Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial With Dose Expansion of Epcoritamab in Combination With Ibrutinib in Refractory/Recurrent CNS Lymphoma (EIFEL-Trial)

NCT07082868 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07082868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07082868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial With Dose Expansion of Epcoritamab in Combination With Ibrutinib in Refractory/Recurrent CNS Lymphoma (EIFEL-Trial)
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
August 13, 2025
Completion date
August 31, 2028
Enrollment
26 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system lymphoma, primary central nervous system lymphoma, primary central nervous system lymphoma (pcnsl), refractory primary central nervous system lymphoma, relapsed primary central nervous system lymphoma, secondary central nervous system lymphoma, secondary central nervous system lymphoma (scnsl)